Skip to content

Efficacy of esketamine in lung protection after total knee replacement in elderly patients

Effect of lower limb ischemia-reperfusion on lung function in elderly patients and optimization of prevention and treatment strategies

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060827
Enrollment
Unknown
Registered
2022-06-12
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee replacement

Interventions

spinal anesthesia+ nerve block+ Esketamine:Esticketamine was given intraoperatively and postoperatively, and nerve block was given postoperatively
spinal anesthesia+ nerve block(N):Postoperative nerve block was given
spinal anesthesia+ Esketamine(S): Esticketamine was administered intraoperatively and postoperatively

Sponsors

The Third Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.TKA patients planned to undergo spinal anesthesia; 2.65 to 90 years old; 3.ASA grade II- III; 4.Voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1.A history of cardiovascular and cerebrovascular adverse events within the past six months, including poorly controlled or untreated hypertension, myocardial infarction, angina pectoris and severe arrhythmia, stroke or transient ischemic attack (TIA); 2.Cognitive dysfunction or mental illness existed before surgery; 3.preoperative anemia, severe liver and kidney diseases; 4.Preoperative pulmonary dysfunction; 5.Infection or immune system disease before surgery; 6.Intraoperative hypoxemia, water and electrolyte disorder, acid-base imbalance; 7.Temporary and permanent pacemaker implantation; 8.Participants in other clinical trials within 1 month prior to enrollment.

Design outcomes

Secondary

MeasureTime frame
Arterial blood gases;IL-6;CRP;TNF-a;SOD;MDA;

Primary

MeasureTime frame
Endothelin 1;NO;

Countries

China

Contacts

Public ContactWang Xiuli
liumengfan0917@163.com+86 18533112928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026